BLACKSMITH MEDICINES, INC.
SAN DIEGO, CA, 92121
Prime contracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. | — | $12,961,082 | Sep 11, 2026 | Sep 21, 2022 – Dec 31, 2026 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | FORGE THERAPEUTICS IS DEVELOPING A PORTFOLIO OF NOVEL, DIRECT-ACTING, SMALL MOLECULE INHIBITORS OF ESSENTIAL METALLOENZYMES FOUND IN HIGH PRIORITY GRAM-NEGATIVE BACTERIA. FORGE€„¢S PLATFORM COMPRISES A DEEP KNOWLEDGE OF METALLOENZYMES, BIOINORGANIC AND MEDICINAL CHEMISTRY KNOW-HOW, AND A FOCUSED FRAGMENT LIBRARY OF PROPRIETARY METAL-BINDING PHARMACOPHORES (MBPS) THAT PROVIDE SELECTIVE AND DIVERSE STARTING POINTS FOR NOVEL INHIBITORS. OUR STRATEGY IS TO FOCUS ON ESSENTIAL METALLOENZYMES FOUND BROADLY ACROSS GRAM-NEGATIVE BACTERIA BUT NOT IN HUMANS. IN BRIEF, OUR LEAD TARGET, LPXC, IS A ZINC METALLOENZYME REQUIRED FOR SYNTHESIS OF THE OUTER MEMBRANE OF GRAM-NEGATIVE BACTERIA. PREVIOUS EFFORTS ON INHIBITING LPXC RELIED ON A HYDROXAMIC ACID (HA) MOIETY TO ANCHOR THE INHIBITOR TO THE CATALYTIC ZINC. ALTHOUGH POTENT IN VITRO, HA-BASED CHEMISTRY SUFFERS IN VIVO FROM GLUCURONIDATION, HYDROLYSIS, AND POOR PK. TO DATE, THERE ARE NO APPROVED ANTIBIOTICS TARGETING LPXC. OUR APPROACH IS TO IDENTIFY NOVEL NON-HA MBPS TO SERVE AS BETTER STARTING POINTS FOR INHIBITOR DEVELOPMENT. FORGE€„¢S GOAL FOR THE FG-LPXC LUNG PROGRAM IS TO DISCOVER AND DEVELOP A NOVEL LPXC INHIBITOR FOR THE TREATMENT OF LUNG INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA WITH A FOCUS ON P. AERUGINOSA. 4500004384 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $41,314 | Oct 16, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.